Should You Buy Oklo Stock While It's Under $171?

Oklo (NYSE: OKLO), a small modular nuclear reactor (SMR) company that went public in 2024 via a SPAC co-founded by Sam Altman, has seen its stock surge due to hype surrounding AI's growing power demands and the potential of SMR technology. Despite recent highs, shares have pulled back from $171 to $120. While Oklo holds nonbinding order agreements, such as with Equinix, commercial operation for a facility is not expected until 2030, suggesting that significant scaling and returns for its under-$20 billion market cap could take years, requiring a long-term investment perspective despite the current valuation pullback.

Analysis

Oklo (NYSE: OKLO), a small modular nuclear reactor (SMR) company that went public in 2024 via a SPAC co-founded by Sam Altman, aims to address the escalating power demands of the artificial intelligence sector. The stock experienced significant volatility, surging to all-time highs of $171 before pulling back to $120 as of November 5th, reflecting initial market enthusiasm followed by a correction.

The company holds nonbinding order agreements, including with data center operator Equinix, yet its first commercial facility is not expected online until 2030. This extended timeline suggests that the widespread scaling of SMR technology and substantial returns for Oklo's sub-$20 billion market capitalization will require considerable patience from investors.

While the SMR sector shows promise, competitors like NuScale Power already have certified reactors in production, and both NuScale and Cameco are recommended by The Motley Fool. Conversely, The Motley Fool Stock Advisor team did not include Oklo in its top 10 stock recommendations, aligning with the moderately negative sentiment and cautious tone surrounding the stock.

Key Decisions for Investors

• Consider Oklo as a long-term, high-risk investment given the 2030 commercialization timeline and current nonbinding agreements.
• Evaluate the recent stock pullback as a potential entry point for investors with a high-risk tolerance and a multi-year horizon.
• Monitor Oklo's progress on securing binding contracts and achieving regulatory milestones, comparing its development trajectory against more established SMR peers like NuScale and Cameco.